Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis

Back to Search
Print
Bookmark Trial

NCT00440492

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Los Angeles, California, 90048, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arthritis, Rheumatoid
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Men or women of nonchildbearing potential with rheumatoid arthritis (RA), aged 18 to 75 years

- RA disease onset after 16 years of age and has had the disease for at least 6 months

- Must be receiving a stable, well-tolerated oral dose of methotrexate (5 to 25 mg) taken once weekly for at least 3 months

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Evidence of unstable clinically significant disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Arthritis, RheumatoidStudy of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate NCT00628095
  1. Mesa, Arizona
  2. Debary, Florida
  3. Lake Mary, Florida
  4. Tampa, Florida
  5. Avon, Indiana
  6. New Orleans, Louisiana
  7. Frederick, Maryland
  8. Columbia, Missouri
  9. Columbia, Missouri
  10. Reno, Nevada
  11. Cincinnati, Ohio
  12. Spokane, Washington
  13. Providencia, Santiago, RM
  14. Ceska Lipa,
  15. Praha 2,
  16. Praha 4,
  17. Incheon,
  18. Pusan,
  19. Mexico, D.f.
  20. Krakow,
  21. Poznan,
  22. Poznan,
  23. Santiago de Compostela, A Coruña
  24. A Coruña,
  25. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidEtanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan) NCT01230177
  1. Sendai, Miyagi
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidStudy of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors NCT00960440
  1. Birmingham, Alabama
  2. Los Angeles, California
  3. Los Angeles, California
  4. San Diego, California
  5. Farmington, Connecticut
  6. Trumbull, Connecticut
  7. Aventura, Florida
  8. Tampa, Florida
  9. Atlanta, Georgia
  10. Boise, Idaho
  11. Idaho Falls, Idaho
  12. Springfield, Illinois
  13. Indianapolis, Indiana
  14. New Orleans, Louisiana
  15. Portland, Maine
  16. Cumberland, Maryland
  17. Worcester, Massachusetts
  18. Flowood, Mississippi
  19. Tupelo, Mississippi
  20. Lebanon, New Hampshire
  21. Voorhees, New Jersey
  22. Rocky Mount, North Carolina
  23. Bethlehem, Pennsylvania
  24. Willow Grove, Pennsylvania
  25. Wyomissing, Pennsylvania
  26. Hixson, Tennessee
  27. Knoxville, Tennessee
  28. Nashville, Tennessee
  29. Dallas, Texas
  30. Dallas, Texas
  31. Fort Worth, Texas
  32. Houston, Texas
  33. Lubbock, Texas
  34. Vancouver, Washington
  35. Vancouver, Washington
  36. Vancouver, Washington
  37. Kogarah, New South Wales
  38. Daw Park, South Australia
  39. Heidelberg, Victoria
  40. Wien,
  41. Wien,
  42. Wien,
  43. Wien,
  44. Genk,
  45. Hasselt,
  46. Kortrijk,
  47. Liège,
  48. Goiania, GO
  49. Curitiba, PR
  50. Porto Alegre, RS
  51. Sao Paulo, SP
  52. Winnipeg, Manitoba
  53. Hamilton, Ontario
  54. Hamilton, Ontario
  55. Ottawa, Ontario
  56. Montreal, Quebec
  57. Pointe Claire, Quebec
  58. Amiens,
  59. Lyon,
  60. Orleans Cedex 1,
  61. Orleans,
  62. Paris,
  63. Paris,
  64. Berlin,
  65. Berlin,
  66. Erlangen,
  67. Frankfurt am Main,
  68. Halle,
  69. Hamburg,
  70. Koeln,
  71. Leipzig,
  72. Rheine,
  73. Wuerzburg,
  74. Croom, Co. Limerick
  75. Dublin,
  76. Firenze,
  77. Jesi,
  78. Busan,
  79. Daegu,
  80. Seoul,
  81. San Juan,
  82. Santiago de Compostela, A Coruña
  83. Merida, Badajoz
  84. Bilbao, Bizkaia
  85. Santander, Cantabria
  86. Baracaldo, Vizcaya
  87. Madrid,
  88. Valencia,
  89. Niao Sung Hsiang, Kaohsiung County
  90. Kweishan, Taoyuan County
  91. Changhua,
  92. Kaohsiung,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidA 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate NCT00847613
  1. Huntsville, Alabama
  2. Tucson, Arizona
  3. San Diego, California
  4. Santa Maria, California
  5. Colorado Springs, Colorado
  6. Gainesville, Florida
  7. Jacksonville, Florida
  8. Sarasota, Florida
  9. Tampa, Florida
  10. Zephyrhills, Florida
  11. Morton Grove, Illinois
  12. Dubuque, Iowa
  13. Lexington, Kentucky
  14. Baltimore, Maryland
  15. Wheaton, Maryland
  16. Worcester, Massachusetts
  17. Bingham Farms, Michigan
  18. Kalamazoo, Michigan
  19. Edina, Minnesota
  20. Columbia, Missouri
  21. Columbia, Missouri
  22. Lee's Summit, Missouri
  23. Omaha, Nebraska
  24. Omaha, Nebraska
  25. Albany, New York
  26. Binghamton, New York
  27. Syracuse, New York
  28. Dayton, Ohio
  29. Pittsburgh, Pennsylvania
  30. Wyomissing, Pennsylvania
  31. Greenville, South Carolina
  32. Knoxville, Tennessee
  33. Dallas, Texas
  34. Houston, Texas
  35. San Antonio, Texas
  36. Clarksburg, West Virginia
  37. Franklin, Wisconsin
  38. Maroochydore, Queensland
  39. Woodville, South Australia
  40. Malvern East, Victoria
  41. Goiania, GO
  42. Curitiba, PR
  43. Porto Alegre, Rio Grande do Sul
  44. Rio de Janeiro, RJ
  45. Porto Alegre, RS
  46. Porto Alegre, RS
  47. Sao Paulo, SP
  48. Sao Paulo, SP
  49. Plovdiv,
  50. Plovdiv,
  51. Sofia,
  52. Sofia,
  53. Edmonton, Alberta
  54. Victoria, British Columbia
  55. St. John's, Newfoundland and Labrador
  56. Hamilton, Ontario
  57. Newmarket, Ontario
  58. Toronto, Ontario
  59. Montreal, Quebec
  60. Quebec,
  61. Medellin, Antioquia
  62. Barranquilla, Atlantico
  63. Bogota, Cundinamarca
  64. Bucaramanga, Santander
  65. Brno - Zidenice,
  66. Brno,
  67. Hostivice,
  68. Pardubice,
  69. Praha 11 - Chodov,
  70. Praha 1,
  71. Praha 2,
  72. Zlin,
  73. Thessaloniki,
  74. Hyderabad, Andhra Pradesh
  75. Secunderabad, Andhra Pradesh
  76. Hyderabad, Andra Pradesh
  77. Bangalore, Karnataka
  78. Bangalore, Karnataka
  79. Mangalore, Karnataka
  80. Pune, Maharashtra
  81. Kitakyusyu, Fukuoka
  82. Higashihiroshima, Hiroshima
  83. Hitachi-shi, Ibaraki
  84. Sagamihara, Kanagawa
  85. Koushi, Kumamoto
  86. Sendai, Miyagi
  87. Ohmura, Nagasaki
  88. Sasebo, Nagasaki
  89. Ureshino-shi, Saga
  90. Kawagoe-shi, Saitama
  91. Hamamatsu, Shizuoka
  92. Bunkyo-ku, Tokyo
  93. Shinjuku-ku, Tokyo
  94. Shinjuku-ku, Tokyo,
  95. Daejeon,
  96. Incheon,
  97. Seoul,
  98. Seoul,
  99. Seoul,
  100. Seoul,
  101. Seoul,
  102. Seoul,
  103. Mexico, DF
  104. Morelia, Michoacan
  105. Warszawa,
  106. Wroclaw,
  107. Kaohsiung,
  108. Kweishan, Taoyuan County,
  109. Taichung,
  110. Tainan,
  111. Taipei,
  112. Taipei,
  113. Simferopol, Crimea
  114. Kharkiv,
  115. Kyiv,
  116. Lviv,
  117. Vinnitsa,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis
Official Title  ICMJE An Open-Label Study To Evaluate The Potential Pharmacokinetic Interaction Between PLA-695 And Methotrexate When Coadministered Orally To Adult Subjects With Rheumatoid Arthritis
Brief Summary The purpose of this study is to determine if PLA-695 changes the blood concentrations of methotrexate when administered together.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Arthritis, Rheumatoid
Intervention  ICMJE Drug: PLA-695
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE Not Provided
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE November 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Men or women of nonchildbearing potential with rheumatoid arthritis (RA), aged 18 to 75 years
  • RA disease onset after 16 years of age and has had the disease for at least 6 months
  • Must be receiving a stable, well-tolerated oral dose of methotrexate (5 to 25 mg) taken once weekly for at least 3 months

Exclusion Criteria:

  • Evidence of unstable clinically significant disease
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00440492
Other Study ID Numbers  ICMJE 3175A3-104
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP